Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vaccine Candidate #4
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
**Vaccine Candidate #4** is an unnamed experimental Pfizer mRNA-based influenza vaccine intervention evaluated as one of six vaccine candidates in the Phase 2 study NCT07431853 in healthy adults. Publicly available trial information does not disclose a molecular identifier, encoded influenza antigen, strain composition, valency, lipid nanoparticle composition, or formulation for this specific candidate; therefore, it cannot be reliably resolved to Pfizer's separately identified influenza mRNA program PF-07252220. ([withpower.com](https://www.withpower.com/trial/phase-2-influenza-human-1-2026-0da63))
Beyond the preview
Go deeper on Vaccine Candidate #4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaccine Candidate #4.